Prelude Therapeutics Inc (PRLD) - Total Liabilities
Based on the latest financial reports, Prelude Therapeutics Inc (PRLD) has total liabilities worth $36.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Prelude Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Prelude Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Prelude Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Prelude Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Prelude Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toubani Resources Ltd
AU:TRE
|
Australia | AU$8.92 Million |
|
Mincon Group plc
IR:MIO
|
Ireland | €57.23 Million |
|
Leoch International Technology Limited
F:0LT
|
Germany | €10.68 Billion |
|
Wam Strategic Value Ltd
AU:WAR
|
Australia | AU$6.49 Million |
|
Ubright Optronics
TWO:4933
|
Taiwan | NT$1.03 Billion |
|
Orthocell Ltd
AU:OCC
|
Australia | AU$20.67 Million |
|
Emilia Devel
TA:EMDV
|
Israel | ILA1.33 Billion |
|
Sam Young Chem
KO:003720
|
Korea | ₩112.72 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Prelude Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Prelude Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prelude Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prelude Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Prelude Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $44.06 Million | +8.58% |
| 2023-12-31 | $40.58 Million | +61.89% |
| 2022-12-31 | $25.06 Million | +30.53% |
| 2021-12-31 | $19.20 Million | +68.33% |
| 2020-12-31 | $11.41 Million | -84.00% |
| 2019-12-31 | $71.28 Million | +82.31% |
| 2018-12-31 | $39.10 Million | -- |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more